I'd just add that ongoing surveillance of this nature is really very key to our life cycle management. I mean, this is why we're asking for these tools, to be able to coordinate.
January 31st, 2008 / 12:55 p.m.
Director, Office of Patented Medicines and Liaison, Therapeutic Products Directorate, Department of Health
I'd just add that ongoing surveillance of this nature is really very key to our life cycle management. I mean, this is why we're asking for these tools, to be able to coordinate.
See context to find out what was said next.